Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma
Top Cited Papers
- 1 May 2004
- journal article
- sarcomas
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (9) , 1706-1712
- https://doi.org/10.1200/jco.2004.08.043
Abstract
Purpose A recent report of the combination of gemcitabine and docetaxel described favorable results in patients with uterine leiomyosarcoma. The objective of this report is to describe experience w...Keywords
This publication has 28 references indexed in Scilit:
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Phase II trial of gemcitabine in advanced sarcomasCancer, 2002
- Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2002
- Combination chemotherapy of the taxanes and antimetabolites: its use and limitationsEuropean Journal Of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Phase II Study of Docetaxel in Advanced Soft Tissue SarcomasAmerican Journal of Clinical Oncology, 1996
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Molecular effects of 2′,2′-difluorodeoxycytidine (gemcitabine) on DNA replication in intact HL-60 cellsBiochemical Pharmacology, 1994
- Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabineCancer Chemotherapy and Pharmacology, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958